BACKGROUND:Non-small-cell lung cancer (NSCLC) predominantly occurs in the elderly, a group that has been historically undertreated for various reasons such as perceived frailty and comorbidity. CASE REPORTS:A series of 5 cases is presented, illustrating the value of erlotinib as a first-line therapy option in elderly patients with adenocarcinoma, who might otherwise have been unsuitable for treatment. A summary of each case is given, along with a discussion of some interesting factors and their clinical relevance to NSCLC therapy. Dose adjustment to manage adverse events is also addressed. CONCLUSION:Erlotinib is an effective and well-tolerated treatment option for NSCLC and could offer an alternative for patients unsuitable for or not wishing to receive chemotherapy.

译文

背景:非小细胞肺癌(NSCLC)主要发生在老年人中,该群体由于各种原因(例如感觉虚弱和合并症)在历史上一直得不到充分治疗。
病例报告:提出了一系列5例病例,说明厄洛替尼作为老年腺癌患者的一线治疗选择的价值,否则他们可能不适合治疗。给出每个病例的摘要,并讨论一些有趣的因素及其与NSCLC治疗的临床相关性。还讨论了管理不良事件的剂量调整。
结论:厄洛替尼是一种有效且耐受良好的非小细胞肺癌的治疗选择,可为不适合或不希望接受化疗的患者提供替代方案。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录